News

Devicemaker Consort buys into the CDMO space with Aesica deal

The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices.

Recipharm trades $140M for a Portuguese CDMO

Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.

Parexel eyes logistics with latest EU expansion

Parexel International has cut the ribbon on a new clinical trial supply hub in Europe, centralizing the CRO's continental logistics services as part of a companywide effort to more efficiently conduct studies around the globe.

Catalent makes another buy and ticks up its revenue

Catalent has acquired another R&D tech firm, snapping up Micron Technologies and its particle sizing capabilities as the recently IPO'd company works to expand its share of the drug development market.

WuXi ups its revenue ambitions after M&A and expansion

Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.

India's GVK snags an early-stage CRO amid global growth

Indian CRO GVK Biosciences is expanding its capacity in early-phase R&D, buying a local preclinical testing outfit as it works to expand its reach.

FDA taps Icon to help patients better weigh in on trials

Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.

PPD teams up with Medidata on risk-based monitoring

PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.

AMRI tanks on disappointing sales and a dimmer outlook

Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.

WuXi reaches into Israel with a new office and a local partnership

Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.

PRA raises the stakes, eyeing $400M in a blockbuster IPO

CRO conglomerate PRA is angling to be the next contract drug developer to make a splash on Wall Street, setting terms for a $400 million IPO.

CRO Paragon raises $13M to expand its footprint

Baltimore CRO Paragon Bioservices has raised a $13 million A round, money it'll spend to stretch out its offerings in biologics R&D and manufacturing.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.

Quintiles posts another $1B quarter and dials up its expectations

Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.

SRI's CRO cuts the ribbon on a new early-phase outpost

SRI International's in-house CRO has opened up a new Phase I center, expanding its footprint in the market for early-stage research.

InVentiv turns to Veeva for cloud-based trial tech

CRO inVentiv Health is dumping out its own trial document storage system and replacing it with Veeva Systems' cloud-based platform, a move the eClinical provider touts as a major affirmation of its technology.

MPI buys out a CRO neighbor to bolster early-stage R&D

MPI Research has acquired fellow Michigan CRO Jasper Clinical Research and Development for an undisclosed sum, a move that will augment the company's offerings in Phase I trials.

CROs line up to advise Big Pharma's R&D think tank

The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.